SCHEMBL4257686

SCHEMBL4257686

O=C(c1ccccc1)C(Br)Cc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.66
CYP1A2 P05177 1/20 0.50
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
ALPI P09923 1/20 0.47
PKM P14618 1/20 0.47
PTGS1 P23219 1/20 0.47
XIAP P98170 1/20 0.47
SLC7A5 Q01650 1/20 0.47
TDP1 Q9NUW8 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CTRB1 P17538 5/20 0.45
KMT2A Q03164 2/20 0.45
CPA1 P15085 2/20 0.44
CPA3 P15088 2/20 0.44
FOLH1 Q04609 1/20 0.44
CPB1 P15086 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11266044 0.88 MDM2 (0.51) MDM2ALDH1A1KMT2ACPA1MMP2
SCHEMBL27719934 0.88 RAB9A (0.56) MDM2CYP1A2MAPTALDH1A1KMT2A
SCHEMBL1303238 0.84 ALDH1A1 (0.56) MDM2CYP1A2MAPTALDH1A1KMT2A
SCHEMBL27529019 0.82 NR4A1 (0.62) CYP1A2PTGS1L3MBTL1ALDH1A1LMNA
SCHEMBL1302717 0.82 CES2 (0.53) MDM2CYP1A2TDP1MAPTALDH1A1
SCHEMBL5610140 0.82 MDM2 (0.68) MDM2CYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL17763412 0.81 CYP1A2 (0.56) MDM2CYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL490844 0.81 CYP1A2 (0.61) MDM2CYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL4826192 0.81 CYP1A2 (0.61) MDM2CYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL4316458 0.81 CYP1A2 (0.61) MDM2CYP1A2SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10036347-A None JP disclosed
JP-5255256-A None JP disclosed
US-20250051296-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2025-02-13 US disclosed
US-12103917-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-10-01 US disclosed
US-20210300882-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-09-30 US disclosed
US-11028061-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2021-06-08 US disclosed
US-20180222874-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Bumham Prebys Medical Discovery Imstitute (US) 2018-08-09 US disclosed
US-20180222874-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Bumham Prebys Medical Discovery Imstitute (US) 2018-08-09 US disclosed
WO-2017019772-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2017-02-02 WO disclosed
WO-2017019772-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2017-02-02 WO disclosed
EP-1423113-A1 NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS LION Bioscience AG (DE) 2004-06-02 EP disclosed
WO-2003097576-A2 DIAMINO-FUNCTIONAL CHALCONES LICA PHARMACEUTICALS A/S (DK) 2003-11-27 WO disclosed
US-20030149087-A1 NR1H4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2003-08-07 US disclosed
WO-2003015777-A1 NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS LION BIOSCIENCE AG (DE) 2003-02-27 WO disclosed
EP-0802184-B1 N-Benzyl-2-phenylindoles as estrogenic agents WYETH CORP (US) 2002-06-19 EP disclosed
CN-1309637-A Compositions comprising 2-phenyl-indole compounds and estrogen formutations AMERICAN HOME PROD (US) 2001-08-22 CN disclosed
EP-1080073-A1 COMPOSITIONS COMPRISING 2-PHENYL-INDOLE COMPOUNDS AND ESTROGEN FORMULATIONS AMERICAN HOME PRODUCTS CORPORATION (US) 2001-03-07 EP disclosed
WO-1999059969-A1 COMPOSITIONS COMPRISING 2-PHENYL-INDOLE COMPOUNDS AND ESTROGEN FORMULATIONS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-25 WO disclosed
JP-H1036347-A ESTROGENLIKE AGENT AMERICAN HOME PROD CORP 1998-02-10 JP disclosed
JP-H05255256-A PYRIDINIUM SALT AND PHOTO-SETTING COMPOSITION COSMO SOGO KENKYUSHO:KK 1993-10-05 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149087-A1 NR1H4 nuclear receptor binding compounds NR1H4, NR1H2, NR1H3 MDM2 4487/4885CYP1A2 341/4885SLC1A3 1185/4885
US-20250051296-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF MYC, MYCBP, MLYCD MDM2 408/4885CYP1A2 3187/4885SLC1A3 1230/4885
US-20210300882-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF MYC, MYCBP, MLYCD MDM2 408/4885CYP1A2 3187/4885SLC1A3 1230/4885
US-20180222874-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF MYC, MYCBP, MLYCD MDM2 408/4885CYP1A2 3187/4885SLC1A3 1230/4885
US-11028061-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof MYC, MYCBP, MLYCD MDM2 408/4885CYP1A2 3187/4885SLC1A3 1230/4885
US-12103917-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof MYC, MYCBP, MLYCD MDM2 408/4885CYP1A2 3187/4885SLC1A3 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.